<?xml version="1.0" encoding="ISO-8859-1" ?><rss version="2.0"><channel><link>http://www.ir.dermasciences.com/profiles/investor/RSSFeeds.asp?BzID=1109</link><title>DERMA SCiENCES News powered by SmartWire</title><description>SmartWire News</description><image><title>SmartWire News</title><url>http://www.b2i.cc/logos/1109/control_logo.jpg</url><link>http://www.ir.dermasciences.com/profiles/investor/RSSFeeds.asp?BzID=1109</link></image><ttl>10</ttl><language>en</language><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=49305&amp;c=440&amp;l=1</guid><title><![CDATA[CORRECTING and REPLACING Derma Sciences to Present at Upcoming Conferences]]></title><pubDate>Wed, 30 Nov 2011 18:10:00 </pubDate><description><![CDATA[
      In second paragraph, time should read 3:00 p.m. Pacific time (sted 3:40 
      p.m. Pacific time)&#160;and webcast link should read http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3742640 
      (sted http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3742420).
    
      The corrected release reads:
    DERMA SCIENCES TO PRESENT AT UPCOMING CONFERENCES
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=49305&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=49297&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at Upcoming Conferences]]></title><pubDate>Wed, 30 Nov 2011 16:19:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will be presenting at two upcoming conferences:
    
      The Canaccord Genuity 6th Annual Cardiovascular, Aesthetics &amp; Metabolic 
      Disorders Conference in San Francisco on December 6, 2011 at 3:40 p.m. 
      Pacific time. The conference is being held at the St. Regis San 
      Francisco. To assess the live webcast of...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=49297&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=49179&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Piper Jaffray 23rd Annual Healthcare Conference]]></title><pubDate>Wed, 23 Nov 2011 12:26:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will be presenting at the Piper Jaffray 23rd Annual Healthcare 
      Conference at 2:00 p.m. EST on November 29, 2011. The conference is 
      being held November 29-30, 2011 at the Palace Hotel in New York City.
    
      Piper Jaffray is using an "unplugged" fireside chat format for the 
      presentation sessions. Edward J....]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=49179&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=48878&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Reports Third Quarter Financial and Operating Results; End-of-Phase 2 Meeting Set with FDA]]></title><pubDate>Fri, 11 Nov 2011 09:00:00 </pubDate><description><![CDATA[Conference call begins at 11:00 a.m. Eastern time today
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today reported financial and 
      operating results for the three and nine months ended September 30, 
      2011. Highlights of the third quarter of 2011 and recent weeks include:
    
        Net sales were $15.8 million, up 5% over the prior-year third quarter
      
        Quarterly net loss increased...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=48878&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=48698&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Lazard Capital Markets 8th Annual Healthcare Conference]]></title><pubDate>Mon, 7 Nov 2011 11:03:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will be presenting at the Lazard Capital Markets 8th Annual Healthcare 
      Conference on Tuesday, November 15, 2011 at 3:00 p.m. ET. The conference 
      is being held November 15-16, 2011 at the Pierre Hotel in New York City. 
      Edward J. Quilty, Chairman and CEO, will deliver the Company's corporate 
      presentation.
 ...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=48698&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=48655&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Lazard Capital Markets 8th Annual Healthcare Conference]]></title><pubDate>Fri, 4 Nov 2011 10:00:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will be presenting at the Lazard Capital Markets 8th Annual Healthcare 
      Conference on Tuesday, November 15, 2011 at 3:00 p.m. ET. The conference 
      is being held September 15-16, 2011 at the Pierre Hotel in New York 
      City. Edward J. Quilty, Chairman and CEO, will deliver the Company's 
      corporate presentation.
...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=48655&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=48595&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Hold Third Quarter Financial Results Conference Call on November 11]]></title><pubDate>Thu, 3 Nov 2011 08:00:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will hold a conference call on November 11, 2011 to discuss the 
      financial results for the third quarter ended September 30, 2011. In 
      addition, management will provide a business update and a discussion on 
      recent and upcoming milestones.
    
      The conference call is scheduled to begin at 11:00 a.m. EST...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=48595&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=47994&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Launches MEDIHONEY&#174; Gel at the Fall Symposium on Advanced Wound Care 2011]]></title><pubDate>Thu, 13 Oct 2011 13:30:00 </pubDate><description><![CDATA[Company Also Highlighting XTRASORB&#174; and 
      MEDIHONEY&#174; Wound Dressings in Poster 
      Presentations
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced the launch of 
      its latest formulation of MEDIHONEY&#174;, the .5 ounce 
      MEDIHONEY Gel, at the Fall 2011 Symposium on Advanced Wound Care (SAWC).
    
      MEDIHONEY Gel is a patented formulation with 80% Active Leptospermum 
    ...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=47994&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=47465&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Jefferies 2011 Global Healthcare Conference]]></title><pubDate>Mon, 26 Sep 2011 09:17:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will be presenting at the Jefferies 2011 Global Healthcare Conference on 
      Tuesday, September 27, 2011 at 5:00 p.m. BST (Noon EDT). The conference 
      is being held September 27-28, 2011 at the Waldorf Hilton Hotel in 
      London, United Kingdom. Edward J. Quilty, Chairman and CEO, will deliver 
      the Company's...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=47465&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=47156&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Rodman &amp; Renshaw 13th Annual Global Investment Conference]]></title><pubDate>Wed, 7 Sep 2011 13:24:00 </pubDate><description><![CDATA[Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and 
      pharmaceutical company focused on advanced wound care, today announced 
      that the company will be participating in the Rodman &amp; Renshaw 13th 
      Annual Global Investment Conference being held at the Waldorf-Astoria 
      Hotel in New York City from September 11th – 13th. Edward J. Quilty, 
      Chairman and CEO, will deliver the Company's corporate presentation on 
      Monday, September 12th, at 10:00 a.m. (Eastern...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=47156&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46825&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Reports Second Quarter Operating Results]]></title><pubDate>Tue, 16 Aug 2011 09:00:00 </pubDate><description><![CDATA[Advanced wound care product sales up 47%, MEDIHONEY&#174; sales 
      up 66%Conference call begins at 11:00 a.m. Eastern time today
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today reported financial and 
      operating results for the three and six months ended June 30, 2011. 
      Highlights of the second quarter of 2011 and recent weeks include:
    
        Net sales were a record $15.9 million, up 20%...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46825&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46663&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 16]]></title><pubDate>Wed, 10 Aug 2011 08:00:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will hold a conference call on August 16, 2011 to discuss the financial 
      results for the second quarter ended June 30, 2011. In addition, 
      management will provide a business update and a discussion on recent and 
      upcoming milestones.
    
      The conference call is scheduled to begin at 11:00 a.m. EDT (Eastern 
...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46663&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46592&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Achieves Key MEDIHONEY&#174; Sales Milestone]]></title><pubDate>Mon, 8 Aug 2011 07:00:00 </pubDate><description><![CDATA[- Triggers Payment to Comvita -
      Derma Sciences, Inc. ("Derma Sciences" or "the Company") (Nasdaq: DSCI), 
      a medical device and pharmaceutical company focused on advanced wound 
      care, today announced it has achieved a key MEDIHONEY&#174; sales milestone 
      and is now on a greater than $7.0 million annual sales run rate. Under 
      the terms of its exclusive worldwide licensing agreement with Comvita 
      New Zealand Ltd., the supplier of medical grade Leptospermum 
    ...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46592&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46469&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Launches Wound Treatment Video Series on eLearning Portal]]></title><pubDate>Tue, 2 Aug 2011 08:30:00 </pubDate><description><![CDATA[Provides New Educational Resources for Clinicians Treating Chronic 
      Wounds and BurnsDerma Sciences, Inc. (Nasdaq: DSCI), a medical device and 
      pharmaceutical company focused on advanced wound care, announces the 
      launch of a new video series library within the Company's eLearning 
      Portal website. The series consists of eight videos including Derma 
      Sciences Commitment to Advanced Wound Care, as well as videos about 
      the Company's leading products;...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46469&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46444&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Receives FDA Clearance for MEDIHONEY&#174; Hydrogel]]></title><pubDate>Mon, 1 Aug 2011 11:18:00 </pubDate><description><![CDATA[Fifth Commercial Product in the MEDIHONEY FranchiseDerma Sciences, Inc. ("Derma Sciences" or "the Company") (Nasdaq: 
      DSCI), a medical device and pharmaceutical company focused on advanced 
      wound care, today announced it has received U.S. Food and Drug 
      Administration 510(k) clearance for its patented MEDIHONEY&#174; Hydrogel 
      Wound and Burn Dressing with Leptospermum (Manuka)honey. 
      This product will be available in both prescription and over-the-counter 
     ...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=46444&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45841&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Closes $29 Million Private Placement Financing]]></title><pubDate>Mon, 27 Jun 2011 07:30:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. ("Derma Sciences" or "the Company") (Nasdaq:DSCI), 
      a medical device and pharmaceutical company focused on advanced wound 
      care, today announced it has closed its previously announced private 
      placement. The financing was led by leading institutional healthcare 
      investors Jennison Associates LLC, RA Capital Management and Deerfield 
      Management. In the offering, the Company raised $29,075,000 by issuing 
      3,524,239 shares of common...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45841&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45842&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Closes $29 Million Private Placement Financing]]></title><pubDate>Mon, 27 Jun 2011 07:30:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. ("Derma Sciences" or "the Company") (Nasdaq:DSCI), 
      a medical device and pharmaceutical company focused on advanced wound 
      care, today announced it has closed its previously announced private 
      placement. The financing was led by leading institutional healthcare 
      investors Jennison Associates LLC, RA Capital Management and Deerfield 
      Management. In the offering, the Company raised $29,075,000 by issuing 
      3,524,239 shares of common...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45842&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45743&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Raises $29 Million in Private Placement Financing]]></title><pubDate>Mon, 20 Jun 2011 09:34:00 </pubDate><description><![CDATA[Proceeds to Be Used to Advance DSC127 into Phase 3 Trials in Diabetic 
      Foot Ulcers and for New Sales Representatives for Advanced Wound Care 
      Products
      Derma Sciences, Inc. ("Derma Sciences" or "the Company") (Nasdaq: DSCI), 
      a medical device and pharmaceutical company focused on advanced wound 
      care, today announced it has entered into definitive agreements with 
      select institutional investors to raise gross proceeds of approximately 
      $29 million. In...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45743&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45394&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Reports Continued Healing at 24 Weeks in Patients with Diabetic Foot Ulcers Treated with DSC127 in Phase 2 Trial]]></title><pubDate>Wed, 25 May 2011 07:00:00 </pubDate><description><![CDATA[Healing spread widens between DSC127 0.03% group and placebo group 
      compared with 12-week dataWounds up to five times more likely to heal at 24 weeks with DSC127 
      0.03% versus placeboConference call begins at 11:00 a.m. Eastern time today
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced that in the 
      follow-up portion of its Phase 2 clinical trial in patients with 
      diabetic foot...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45394&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45388&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Hold Conference Call Tomorrow, May 25 to Discuss 24-Week Data from Phase 2 DSC127 Trial in Diabetic Foot Ulcers]]></title><pubDate>Tue, 24 May 2011 16:10:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, will issue a news release 
      announcing 24-week data from its Phase 2 trial with DSC127 in diabetic 
      foot ulcers at 7:00 a.m. Eastern time Wednesday, May 25 and will hold a 
      conference call to discuss those results at 11:00 a.m. Eastern time that 
      same day.
    
      To participate in the conference call, from the U.S. please dial (888) 
     ...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45388&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45227&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Noble Financial Capital Markets' Seventh Annual Equity Conference]]></title><pubDate>Fri, 13 May 2011 13:43:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will be presenting at the Noble Financial Capital Markets' Seventh 
      Annual Equity Conference being held at the Seminole Hard Rock Hotel &amp; 
      Casino in Hollywood, Fla. on May 16 and 17. Barry Wolfenson, Derma 
      Sciences' Executive Vice President of Global Marketing &amp; Business 
      Development will deliver...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45227&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45140&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences First Quarter Results Feature Positive Cash Flow from Operations, Advanced Wound Care Product Sales up 57%, Total Sales up 12%]]></title><pubDate>Wed, 11 May 2011 07:30:00 </pubDate><description><![CDATA[Conference call begins at 11:00 a.m. Eastern time today
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today reported financial and 
      operating results for the three months ended March 31, 2011. Highlights 
      of the first quarter of 2011 and recent weeks include:
    
        Net cash generated from operations was $1.1 million
      
        Working capital increased $663,127 to $10,607,056 as of March 31,...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45140&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45032&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Hold First Quarter Financial Results Conference Call on May 11]]></title><pubDate>Fri, 6 May 2011 07:30:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will hold a conference call on May 11, 2011 to discuss the financial 
      results for the first quarter ended March 31, 2011. In addition, 
      management will provide a business update and a discussion on recent and 
      upcoming milestones.
    
      The conference call is scheduled to begin at 11:00 a.m. EDT (Eastern 
   ...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=45032&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44690&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences MEDIHONEY&#174; and XTRASORB&#174; Posters and Expert Presentations Featured at Symposium on Advanced Wound Care 2011]]></title><pubDate>Mon, 18 Apr 2011 08:30:00 </pubDate><description><![CDATA[MEDIHONEY&#174; poster awarded first place 
      in Case Series category
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced that poster and 
      expert presentations featuring MEDIHONEY&#174; and XTRASORB&#174;, 
      two of the commercial products in the Company's full line of advanced 
      wound care dressings, were highlighted at the Symposium on Advanced 
      Wound Care (SAWC) Spring 2011 held...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44690&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44609&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference]]></title><pubDate>Tue, 12 Apr 2011 10:12:00 </pubDate><description><![CDATA[http://media.marketwire.com/attachments/200604/255884_stacked-logo.gif -->http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=743574&amp;ProfileId=051205&amp;sourceType=1 -->NEW YORK, NY -- (Marketwire) -- 04/12/11 --   Taglich Brothers, Inc. is pleased to announce that Edward J. Quilty, President &amp; CEO of Derma Sciences, Inc. (NASDAQ: DSCI) will be presenting at our 8th Annual Small Cap Equity Conference May 3rd, 2011. The Conference will take place at the New York...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44609&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44376&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Reports Fourth Quarter Results; Sales of Advanced Wound Care Products up 59% over Prior Year; Total Net Sales New Record for Quarter]]></title><pubDate>Wed, 30 Mar 2011 07:30:00 </pubDate><description><![CDATA[Conference Call Begins at 11:00 A.M. Eastern Time Today
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today reported financial and 
      operating results for the three and 12 months ended December 31, 2010. 
      Highlights of the fourth quarter of 2010 and recent weeks include:
    
        Reported positive top-line results from its Phase 2 trial with DSC127 
        for treating diabetic foot ulcers, including...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44376&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44355&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Advanced Wound Care Products Featured in Five Poster Presentations at the Diabetic Foot Global Conference 2011]]></title><pubDate>Tue, 29 Mar 2011 07:30:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced that five 
      scientific abstracts based on commercial and development-stage products 
      in the Company's line of wound dressings were presented at the annual 
      Diabetic Foot Global Conference (DFCON), held in Los Angeles March 
      24-26. For complete information on all five abstracts, please visit the 
      DFCON website at...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44355&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44265&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Announces Fourth Quarter 2010 Financial Results Conference Call]]></title><pubDate>Wed, 23 Mar 2011 10:45:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will hold a conference call on March 30, 2011 to discuss the financial 
      results for the fourth quarter ended December 31, 2010. In addition, 
      management will provide a business update and a discussion on recent and 
      upcoming milestones.
    
      The conference call is scheduled to begin at 11:00 a.m. ET (Eastern...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=44265&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43968&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Roth Capital Partners Growth Stock Conference]]></title><pubDate>Tue, 8 Mar 2011 09:32:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care announced today that the Company 
      will be presenting at the ROTH Capital Partners 23rd Annual OC Growth 
      Stock Conference being held at the Ritz Carlton in Dana Point, Calif. 
      from March 14 through 16. Edward J. Quilty, Derma Sciences' president 
      and chief executive officer, will deliver the Company's corporate 
      presentation on Tuesday,...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43968&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43779&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Receives FDA Clearance for MEDIHONEY&#174; Gel]]></title><pubDate>Mon, 28 Feb 2011 07:30:00 </pubDate><description><![CDATA[Fourth Product in MEDIHONEY Franchise Will Expand Market and 
      Strengthen Brand Leadership Position
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced receipt of 
      510(k) clearance from the U.S. Food and Drug Administration (FDA) for 
      the Company's patent-pending MEDIHONEY&#174; Gel Wound and Burn Dressing. 
      This latest MEDIHONEY line extension is dispensed from a tube and is 
     ...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43779&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43649&amp;c=440&amp;l=1</guid><title><![CDATA[Department of Health and Human Services Grants $4.5 Million to Research DSC127 in Skin Injuries Associated with Acute Radiation Exposure]]></title><pubDate>Tue, 22 Feb 2011 07:30:00 </pubDate><description><![CDATA[- Preclinical Work to Expand Potential of DSC127 in Additional 
      Indications -
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced that researchers 
      who invented DSC127 have been awarded a $4.5 million, 16-month grant by 
      the U.S. Department of Health and Human Services' (HHS) Biomedical 
      Advanced Research and Development Authority (BARDA) to investigate 
      preclinically the use...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43649&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43558&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Lippert/Heilshorn Life Sciences &amp; Medtech Virtual Conference on February 17]]></title><pubDate>Wed, 16 Feb 2011 07:00:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced that Edward J. 
      Quilty, president and chief executive officer, will present to investors 
      as part of the Lippert/Heilshorn &amp; Associates Life Sciences &amp; Medical 
      Technologies On-line Forum on Thursday, February 17, 2011 at 1:30 p.m. 
      Eastern. The presentation will provide a corporate overview and a 
      discussion of the...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43558&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43279&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Reports Positive Top-Line Results from DSC127 Phase 2 Trial in Patients with Diabetic Foot Ulcers]]></title><pubDate>Thu, 3 Feb 2011 07:00:00 </pubDate><description><![CDATA[Drug meets primary efficacy endpointWounds up to three times more likely to healConference call begins at 10:00 a.m. Eastern time today
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced positive results 
      from its Phase 2 clinical trial with DSC127 in patients with diabetic 
      foot ulcers, including meeting the trial's primary endpoint, the 
      proportion of study ulcers healed by 12 weeks as...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43279&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43264&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Hold Conference Call to Discuss Results from Phase 2 DSC127 Trial in Diabetic Foot Ulcers February 3]]></title><pubDate>Wed, 2 Feb 2011 16:05:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, will issue a news release 
      announcing top-line efficacy results from its Phase 2 trial with DSC127 
      in diabetic foot ulcers at 7:00 a.m. Eastern time Thursday, February 3 
      and will hold a conference call to discuss those results at 10:00 a.m. 
      Eastern time that same day.
    
      To participate in the conference call, from the U.S. please dial...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=43264&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=42780&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Launches Advanced Wound Care eLearning Portal for Clinicians]]></title><pubDate>Tue, 4 Jan 2011 08:30:00 </pubDate><description><![CDATA[New Content-Rich Website Provides Educational Support and Resources 
      to Meet the Ever-Changing Needs of Patients with Chronic Wounds
      Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, announces the launch of a new 
      eLearning Portal to provide clinicians with valuable educational 
      programs to ensure they are kept abreast of the latest information and 
      product solutions in the Company's advanced...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=42780&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=42779&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Launches Advanced Wound Care eLearning Portal for Clinicians]]></title><pubDate>Tue, 4 Jan 2011 08:30:00 </pubDate><description><![CDATA[New Content-Rich Website Provides Educational Support and Resources 
      to Meet the Ever-Changing Needs of Patients with Chronic Wounds
      Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, announces the launch of a new 
      eLearning Portal to provide clinicians with valuable educational 
      programs to ensure they are kept abreast of the latest information and 
      product solutions in the Company's advanced...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=42779&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41801&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Fourth Annual Maxim Group Growth Conference]]></title><pubDate>Tue, 16 Nov 2010 15:57:00 </pubDate><description><![CDATA[Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and 
      pharmaceutical company focused on advanced wound care, today announced 
      that the company will be participating in the Fourth Annual Maxim Group 
      Growth Conference being held at the Grand Hyatt New York in New York 
      City on Thursday, November 18, 2010. John E. Yetter, chief financial 
      officer, will deliver the Company's corporate presentation on Thursday, 
      November 18, at 9:30 a.m. (Eastern Time).
   ...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41801&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41720&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Reports Third Quarter Net Sales Up 17%, Advanced Wound Care Sales Up 38%]]></title><pubDate>Fri, 12 Nov 2010 09:09:00 </pubDate><description><![CDATA[Conference Call Begins at 11:00 a.m. Eastern Time Today
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today reported financial and 
      operating results for the three and nine months ended September 30, 
      2010. Highlights of the third quarter of 2010 and recent weeks include:
    
        Net sales increased 17% to $15.1 million from $12.9 million in the 
        third quarter of 2009
      
        Advanced...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41720&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41539&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Announces Third Quarter 2010 Results Conference Call]]></title><pubDate>Fri, 5 Nov 2010 10:57:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, will hold a conference call on 
      November 12, 2010 to discuss the financial results for the third quarter 
      ended September 30, 2010. In addition, management will provide a 
      business update and a discussion on recent and upcoming milestones.
    
      The conference call is scheduled to begin at 11:00 a.m. EST (Eastern 
      Standard Time). The results...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41539&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41447&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Awarded $244,479 from U.S. Government under the Patient Protection and Affordable Care Act]]></title><pubDate>Wed, 3 Nov 2010 08:50:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced that it has been 
      awarded a research and development grant of $244,479 from the U.S. 
      government under HR: 3590 – Patient Protection and Affordable Care Act 
      (the "Act") in immediately available funds.
    
      Under the Act, $1 billion was earmarked for qualifying therapeutic 
      discovery projects that treat areas of unmet...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41447&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41448&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Awarded $244,479 from U.S. Government under the Patient Protection and Affordable Care Act]]></title><pubDate>Wed, 3 Nov 2010 08:50:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced that it has been 
      awarded a research and development grant of $244,479 from the U.S. 
      government under HR: 3590 – Patient Protection and Affordable Care Act 
      (the "Act") in immediately available funds.
    
      Under the Act, $1 billion was earmarked for qualifying therapeutic 
      discovery projects that treat areas of unmet...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=41448&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=40407&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Complete Enrollment in DSC127 Phase 2 Wound Healing Trial This Month]]></title><pubDate>Tue, 14 Sep 2010 07:30:00 </pubDate><description><![CDATA[Top-line Efficacy Results to be Available Late December/Early January
      Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today announced that patient 
      screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing 
      will be completed tomorrow, and that enrollment in the trial will 
      conclude on September 30. This randomized, double-blind, placebo 
      controlled study of up to 75 patients will look...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=40407&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=40296&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences to Present at the Rodman &amp; Renshaw 12th Annual Global Investment Conference]]></title><pubDate>Tue, 7 Sep 2010 10:30:00 </pubDate><description><![CDATA[Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and 
      pharmaceutical company focused on advanced wound care, today announced 
      that the company will be participating in the Rodman &amp; Renshaw 12th 
      Annual Global Investment Conference being held at the Palace Hotel in 
      New York City from September 13th – 15th, 2010. Edward J. Quilty, 
      Chairman and CEO, will deliver the Company's corporate presentation on 
      Tuesday, September 14th, at 11:15 a.m. (Eastern...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=40296&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=40228&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Novel XTRASORB&#174; HCS Dressings Receive Federal Reimbursement Codes; Join Foam and Classic Dressings for Complete Coverage of Product Category]]></title><pubDate>Thu, 2 Sep 2010 11:56:00 </pubDate><description><![CDATA[Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and 
      pharmaceutical company focused on advanced wound care, announces that 
      all five products in its novel line of XTRASORB&#174; HCS Dressings have 
      received Healthcare Common Procedural Coding System (HCPCS) codes. These 
      codes – A6234 through A6238 – were awarded by the Centers for Medicare 
      and Medicaid Services (CMS), and allow healthcare providers to bill for 
      the dressings beginning immediately....]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=40228&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=39939&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Second Quarter Results Feature Net Sales Up 14%; Advanced Wound Care Sales Up 47%]]></title><pubDate>Fri, 13 Aug 2010 07:00:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, today reported financial and 
      operating results for the three and six months ended June 30, 2010. 
      Highlights of the second quarter of 2010 and recent weeks include:
    
        Net sales increased 14% to $13.2 million from $11.6 million in the 
        second quarter of 2009.
      
        Advanced wound care sales were $2.6 million, up 47% from $1.7...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=39939&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=39820&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Announces Second Quarter 2010 Results Conference Call]]></title><pubDate>Mon, 9 Aug 2010 08:45:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, will hold a conference call on 
      August 13, 2010 to discuss the financial results for the second quarter 
      ended June 30, 2010. In addition, management will provide a business 
      update and a discussion on recent and upcoming milestones.
    
      The conference call is scheduled to begin at 11:00 a.m. EDT (Eastern 
      Daylight Time). The results will...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=39820&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=39313&amp;c=440&amp;l=1</guid><title><![CDATA[Webcast Alert: Derma Sciences, Inc. Announces the LHA Life Sciences &amp; Med Tech Day 2010 Presentation]]></title><pubDate>Wed, 14 Jul 2010 17:34:00 </pubDate><description><![CDATA[NEW YORK, July 14 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI) announces the following Webcast:What:LHA Life Sciences &amp; Med Tech Day 2010 PresentationWhen:July 20, 2010 @ 11:30 AM EasternWhere:http://www.investorcalendar.com/ClientPage.asp?ID=160488How:Live over the Internet -- Simply log on to the web at the address above.Contact:Cheryl Palazzo, 212-838-3777, cpalazzo@lhai.comIf you are unable to participate during the live webcast, the call will be available for replay at...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=39313&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=39237&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Submits 510(k) Application for MEDIHONEY Gel, Reaches Goal of 20-Person U.S. Field Sales Force]]></title><pubDate>Fri, 9 Jul 2010 07:30:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (NASDAQ: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, announces the achievement of 
      regulatory and commercial milestones.
    
      Late last week the Company submitted a 510(k) application to the U.S. 
      Food and Drug Administration (FDA) for MEDIHONEY&#174; Gel Wound &amp; Burn 
      Dressing. This latest MEDIHONEY line extension is dispensed from a tube 
      and is comprised of Active Manuka (Leptospermum)...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=39237&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=38994&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Added to Russell Microcap Index]]></title><pubDate>Mon, 28 Jun 2010 07:25:00 </pubDate><description><![CDATA[
      Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, announced today that the 
      Company's common stock has been added to the Russell Microcap&#174; Index 
      posted by Russell Investments on www.russell.com. 
      These changes went into effect after the close of trading on Friday, 
      June 25, 2010.
    
      'Inclusion in this index represents an important step in the growth of 
      Derma Sciences and we...]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=38994&amp;c=440&amp;l=1</link></item><item><guid isPermaLink="true">http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=38882&amp;c=440&amp;l=1</guid><title><![CDATA[Derma Sciences Announces Issuance of Second U.S. Patent Related to MEDIHONEY Alginate Dressing]]></title><pubDate>Tue, 22 Jun 2010 07:30:00 </pubDate><description><![CDATA[Further Strengthens Intellectual Property on Company's Lead Product
      Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical 
      company focused on advanced wound care, announces that the U.S. Patent 
      and Trademark Office has issued patent No. 7,714,183 related to the 
      Company's MEDIHONEY&#174; Calcium Alginate Dressing.
    
      This is the second patent granted in the U.S. covering Derma Sciences' 
      line of proprietary honey-based wound dressings....]]></description><link>http://www.ir.dermasciences.com/irpass.asp?BzID=1109&amp;to=rl&amp;ResLibraryID=38882&amp;c=440&amp;l=1</link></item></channel></rss>
